PotlatchDeltic Corporation (Nasdaq:PCH) today confirmed that a fire occurred at its Ola, Arkansas sawmill on the morning of Sunday June 13. The Ola and Galla Rock Fire Departments responded quickly and brought the fire under control. There were no injuries reported from the fire or environmental issues. The damage was principally to the primary log breakdown area of the mill. The planer mill, kiln, and shipping department were not affected. Processing of existing rough lumber inventories will be completed as soon as possible. A determination regarding downtime and costs to repair the Ola mill will be made as the extent of damage is fully assessed. We are preparing an insurance claim, including business interruption. PotlatchDeltic log deliveries will be diverted to other mills in the area as much as possible, however harvesting operations may be impacted.

The Ola, Arkansas sawmill employs approximately 148 people in the mill and wood procurement operations. The sawmill has the capacity to produce approximately 150 million board feet of lumber a year. PotlatchDeltic is committed to its operations in Ola and will be assessing options and timing for repair to the damaged areas. Our thanks go out to our employees and contractors who were on site and the Ola Fire Department and Galla Rock Volunteer Fire Department for their prompt response to the fire.

About PotlatchDeltic

PotlatchDeltic (Nasdaq:PCH) is a leading Real Estate Investment Trust (REIT) that owns approximately 1.8 million acres of timberlands in Alabama, Arkansas, Idaho, Louisiana, Minnesota and Mississippi. Through its taxable REIT subsidiary, the company also operates six sawmills, an industrial-grade plywood mill, a residential and commercial real estate development business and a rural timberland sales program. PotlatchDeltic, a leader in sustainable forest practices, is committed to environmental and social responsibility and to responsible governance. More information can be found at www.potlatchdeltic.com.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as amended, including without limitation, our expectations regarding the impact of the fire at our Ola, Arkansas sawmill, including downtime, costs and timing for repairs, insurance claims, and similar matters. Words such as “will,” and similar expressions are intended to identify such forward-looking statements. You should carefully read forward-looking statements, including statements that contain these words, because they discuss the future expectations or state other “forward-looking” information about PotlatchDeltic. A number of important factors could cause actual results or events to differ materially from those indicated by such forward-looking statements, many of which are beyond PotlatchDeltic’s control, including the impact of the fire at our Ola, Arkansas sawmill, including downtime, costs and timing for repairs, and similar matters; the company’s ability to meet expectations; and the other factors described in PotlatchDeltic’s Annual Report on Form 10-K and in the company’s other filings with the SEC. PotlatchDeltic assumes no obligation to update the information in this communication, except as otherwise required by law. Readers are cautioned not to place undue reliance on these forward-looking statements, all of which speak only as of the date hereof.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210613005042/en/

Read more: PotlatchDeltic Reports Fire Damage At Ola, Arkansas Sawmill

AURORA, Ill., June 13, 2021 /PRNewswire/ — Versiti Blood Center of Illinois is issuing an emergency appeal for blood donations as communities across the state face a potential crisis with blood supplies dropping to critically low levels. All blood types are needed with type O-negative and O-positive blood most in demand.

“As COVID-19 restrictions ease, allowing people to gather again and enjoy all that an Illinois summer has to offer, the attention has shifted away from blood donation, creating a crisis for the state’s blood supply,” said Dr. Dan Waxman, vice president of transfusion medicine and senior medical director at Versiti. “We are urgently seeking help from our loyal donors and the public and asking that anyone able to please donate blood today. Your donation is vital to ensure that Illinois hospitals have the blood they need for their patients.”

In Illinois, the state’s blood supply has dropped to a critically low level. There is less than a day’s supply of life-saving blood on shelves to supply Versiti’s more than 86 hospital partners throughout the state. Ideally, Versiti strives for a three-day supply of blood available to its partner hospitals.

Compared to a typical year, Versiti Blood Centers is down more than 40 percent in donations – or nearly 20,000 units of blood – while the need for blood has increased nearly 10 percent over historical averages.

Blood donors are needed now to help ensure life-saving blood is available for Illinoisians who need it. One donation of blood, which takes less than one hour, can help save up to three lives.

O-negative and O-positive blood donors are most needed now. O-negative blood is the universal blood type, meaning donations can be transfused to all patients, including trauma victims, cancer patients and those undergoing surgery.

Effective June 14 – 21, Versiti is expanding capacity and extending hours at its centers to help with donation collection. We ask that donors visit a Versiti Blood Center of Illinois donor facility nearest to them:

• WESTMONT: 6317 S. Fairview
• TINLEY PARK: 16100 Centennial Circle
• BLOOMINGDALE: 204 Gary Ave.
• NAPERVILLE: 1297 S. Naper Blvd.
• WINFIELD: 27W281 Geneva Rd.
• JOLIET: 2625 W. Jefferson St.
• GENEVA: 2000 W. State St., Unit 1E
• AURORA: 1200 N. Highland Ave.
• ELGIN: 1140 N. McLean Blvd.
• CRYSTAL LAKE: 6296 Northwest Hwy.
• YORKVILLE: 728 E. Veterans Pkwy., Suite 112
• DEKALB: 2428 Sycamore Rd.
• HIGHLAND: 2126 45th Street

Illinois residents can also make an appointment to donate at a local community blood drive in their area. Times, dates and locations of upcoming local drives can be found online at https://donate.illinois.versiti.org. Interested donors should click the “Schedule to Donate” tab to find the nearest drive to them.

Donating blood takes about an hour with the actual donation taking 10 – 5 minutes. Anyone age 17 or older in good health who meets eligibility requirements is encouraged to give. Parental consent is required for donors age 16 to donate blood. Donors should bring a photo ID that includes their birth date.

Donors who are fully vaccinated are not required to wear a face covering while in Versiti facilities. Non-vaccinated donors are asked to continue to wear a face covering, except where medical conditions prevent them from wearing one. All Versiti donation locations are practicing social distancing and closely adhering to FDA and CDC cleaning and disinfecting protocols.

Appointments are encouraged at any of Versiti’s Illinois donor centers or any local community blood drive. Walk-ins are always welcome. To schedule an appointment to donate blood, call 1-866-642-5663 or visit Versiti online at versiti.org/IL.

ABOUT VERSITI BLOOD CENTER OF ILLINOISVersiti Blood Center of Illinois is a not-for-profit organization headquartered in Aurora, IL., that specializes in blood products and services and provides expert medical and technical support. Founded in 1943, it is the oldest blood center in Illinois and serves patients at 86 hospitals in Chicagoland and Northwest Indiana. It operates 13 donor centers and conducts nearly 2,200 blood drives annually at area hospitals, churches, businesses, schools and community centers. To learn more, visit versiti.org/IL.

View original content to download multimedia: http://www.prnewswire.com/news-releases/less-than-a-days-supply-of-blood-now-on-illinois-shelves-301311347.html

SOURCE Versiti Blood Center of Illinois

Read more: Less Than A Day’s Supply Of Blood Now On Illinois Shelves

MILWAUKEE, June 13, 2021 /PRNewswire/ — Versiti Blood Center of Wisconsin is issuing an emergency appeal for blood donations as communities across the state face a potential crisis with blood supplies dropping to critically low levels. All blood types are needed with type O-negative and O-positive blood most in demand.

“As COVID-19 restrictions ease, allowing people to gather again and enjoy all that a Wisconsin summer has to offer, the attention has shifted away from blood donation, creating a crisis for the state’s blood supply,” said Dr. Dan Waxman, vice president of transfusion medicine and senior medical director at Versiti. “We are urgently seeking help from our loyal donors and the public and asking that anyone able, to please donate blood today. Your donation is vital to ensure that Wisconsin hospitals have the blood they need for their patients.”

In Wisconsin, the state’s blood supply has dropped to a critically low level, with less than a day’s supply of life-saving blood on shelves to supply Versiti’s more than 68 hospital partners throughout the state. Ideally, Versiti strives for a three-day supply of blood available to its partner hospitals.

Compared to a typical year, Versiti Blood Centers is down more than 40 percent in donations – or nearly 20,000 units of blood – while the need for blood has increased nearly 10 percent over historical averages.

Blood donors are needed now to help ensure life-saving blood is available for Wisconsinites who need it. One donation of blood, which takes less than one hour, can help save up to three lives.

O-negative and O-positive blood donors are most needed now. O-negative blood is the universal blood type, meaning donations can be transfused to all patients, including trauma victims, cancer patients and those undergoing surgery.

Effective June 14 – 21, Versiti is expanding capacity and extending hours at its centers to help with donation collection. We ask that donors visit a Versiti Blood Center of Wisconsin donor facility nearest to them:

• GREENFIELD: 7210 W. Edgerton Avenue
• KENOSHA: 8064 39th Avenue
• MARSHFIELD: 508 N. Central
• MANITOWOC: 619 Reed Avenue
• MILWAUKEE: 638 North 18th Street
• RACINE: 1120 S. Sunnyslope Drive
• WAUKESHA: 2111 Springdale Road
• WEST BEND: 130 Valley Avenue
• WAUWATOSA: 8733 Watertown Plank Road

Wisconsin residents can also make an appointment to donate at a local community blood drive in their area. Times, dates and locations of upcoming local drives can be found online at https://donate.wisconsin.versiti.org/. Interested donors should click the “Schedule to Donate” tab to find the nearest drive to them.

Donating blood takes about an hour with the actual donation taking 10-15 minutes. Anyone age 17 or older in good health who meets eligibility requirements is encouraged to give. Parental consent is required for donors age 16 to donate blood. Donors should bring a photo ID that includes their birth date.

Donors who are fully vaccinated are not required to wear a face covering while in Versiti facilities. Non-vaccinated donors are asked to continue to wear a face covering, except where medical conditions prevent them from wearing one. All Versiti donation locations are practicing social distancing and closely adhering to FDA and CDC cleaning and disinfecting protocols.

Appointments are encouraged at any of Versiti’s Wisconsin donor centers or any local community blood drive. Walk-ins are always welcome. To schedule an appointment to donate blood, call 1-866-642-5663 or visit Versiti online at versiti.org/WI.

ABOUT VERSITI BLOOD CENTER OF WISCONSINVersiti Blood Center of Wisconsin is a not-for-profit organization headquartered in Milwaukee that specializes in blood services, esoteric diagnostic testing, organ, tissue and stem cell donation, medical services and leading-edge research. We advance patient care by delivering life-saving products and services. For more information, visit versiti.org/WI.

View original content to download multimedia: http://www.prnewswire.com/news-releases/less-than-a-days-supply-of-blood-now-on-wisconsin-shelves-301311346.html

SOURCE Versiti Blood Center of Wisconsin

Read more: Less Than A Day’s Supply Of Blood Now On Wisconsin Shelves

NEW ORLEANS, June 13, 2021 /PRNewswire/ — Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have only until June 14, 2021 to file lead plaintiff applications in a securities class action lawsuit against Canaan Inc. (NasdaqGM: CAN), if they purchased the Company’s American Depositary Receipts (“ADRs”) between February 10, 2021 and April 9, 2021, inclusive (the “Class Period”).  This action is pending in the United States District Court for the Southern District of New York.

What You May Do

If you purchased ADRs of Canaan and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ( lewis.kahn@ksfcounsel.com), or visit https://www.ksfcounsel.com/cases/nasdaqgm-can/ to learn more. If you wish to serve as a lead plaintiff in this class action by overseeing lead counsel with the goal of obtaining a fair and just resolution, you must request this position by application to the Court by June 14, 2021 .

About the Lawsuit

Canaan and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws. On April 12, 2021, pre-market, the Company disclosed dismal 4Q20 and FY20 financial results for the period ended December 31, 2020, including a 93% year-over-year decrease in computing power sold and net revenues for the quarter, a stark contrast to the Company’s prior positive statements touting its business metrics and financial prospects. On this news, ADRs of Canaan plummeted nearly 30%, from a close of $18.67 per ADR on April 9, 2021 to close at $13.14 on April 12, 2021, on unusually high volume.

The case is Denny v. Canaan Inc., No. 21-cv-03299.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. KSF serves a variety of clients – including public institutional investors, hedge funds, money managers and retail investors – in seeking to recover investment losses due to corporate fraud and malfeasance by publicly traded companies. KSF has offices in New York, California and Louisiana.

To learn more about KSF, you may visit www.ksfcounsel.com.

Contact:

Kahn Swick & Foti, LLC Lewis Kahn, Managing Partner lewis.kahn@ksfcounsel.com 1-877-515-18501100 Poydras St., Suite 3200 New Orleans, LA 70163

View original content to download multimedia: http://www.prnewswire.com/news-releases/canaan-24-hour-deadline-alert-former-louisiana-attorney-general-and-kahn-swick–foti-llc-remind-investors-with-losses-in-excess-of-100-000-of-deadline-in-class-action-lawsuit-against-canaan-inc—can-301310607.html

SOURCE Kahn Swick & Foti, LLC

Read more: CANAAN 24 HOUR DEADLINE ALERT: FORMER LOUISIANA ATTORNEY GENERAL AND KAHN SWICK & FOTI, LLC REMIND INVESTORS WITH LOSSES IN EXCESS OF 0,000 Of Deadline In Class Action Lawsuit Against Canaan Inc. – CAN

SEONGNAM, South Korea, June 13, 2021 /PRNewswire/ — Bridge Biotherapeutics (KQ288330) announced today the first patient dosing of BBT-401 at mid to high doses in its proof of clinical principle (PoCP) study to examine the drug’s efficacy and safety in active ulcerative colitis (NCT04596293).

The Phase IIa, is a two-phase study, with a randomized, double-blind, placebo-controlled induction phase, followed by a response-adaptive, double-blind extension phase. This multinational study will assess the safety and efficacy profiles of the investigational drug in 36 patients with moderate to severe ulcerative colitis, by activating 36 clinical trial sites across 5 countries ( USA, Republic of Korea, New Zealand, Poland and Ukraine).

The primary and secondary endpoints of the study consist of efficacy and safety assessments measured 8 weeks after drug administration. These include the clinical response and remission rates determined from the total Mayo score as well as the endoscopic remission rate, which is calculated based on the Mayo endoscopic subscore.

Upon the completion of the low dose study, which was the first-in-patient study for BBT-401, the drug formulation has been enhanced in terms of its drug delivery and distribution to the ileum and distant colon. The enhanced drug delivery and distribution profile was evaluated via the in vitro Simulator of the Human Intestinal Microbial Ecosystem (SHIME ®) model.

BBT-401, an investigational drug with the potential to exhibit treatment efficacy in inflammatory diseases such as ulcerative colitis, is a GI-tract restricted small molecule Pellino-1 inhibitor. Pellino proteins serve as scaffold proteins that bind to proteins in inflammatory signaling pathways, including IRAK4, MyD88 and to RIPK1 in various physio-pathological conditions.

“Given the improved drug formulation of BBT-401, we are hoping to observe enhanced treatment responses in the moderate to severe UC patients,” and “our team will continue to focus on the development of a breakthrough treatment for active ulcerative colitis patients. Additionally, our goal is to disclose the interim data of the study in the first half of 2022,” said James Lee, CEO of Bridge Biotherapeutics.

In conjunction with the orally administered PoCP study, a proof of mechanism trial has been initiated in New Zealand, exploring the efficacy and safety of a rectal administration of BBT-401 in patients with active ulcerative colitis.

About Bridge Biotherapeutics

Bridge Biotherapeutics Inc., based in the Republic of Korea, US, and China, is a publicly-traded clinical-stage biotech company founded in 2015. Bridge Biotherapeutics is engaged in the discovery and development of novel therapeutics, focusing on therapeutic areas with high unmet needs such as ulcerative colitis, fibrotic diseases, and cancers. The company is developing BBT-401, a first-in-class Pellino-1 inhibitor for the treatment of ulcerative colitis, BBT-877, a novel autotaxin inhibitor for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF), and BBT-176, a potent targeted cancer therapy for non-small cell lung cancer (NSCLC) with C797S triple EGFR mutations.

View original content: http://www.prnewswire.com/news-releases/bridge-biotherapeutics-announces-the-initiation-of-patient-dosing-in-the-proof-of-clinical-principle-study-for-bbt-401-an-investigational-drug-for-ulcerative-colitis-301311202.html

SOURCE Bridge Biotherapeutics, Inc.

Read more: Bridge Biotherapeutics Announces The Initiation Of Patient Dosing In The Proof Of Clinical Principle Study For BBT-401, An Investigational Drug For Ulcerative Colitis

VANCOUVER, British Columbia, June 12, 2021 (GLOBE NEWSWIRE) — Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the ” Company“) is pleased to announce that its wholly-owned subsidiary Vocan Biotechnologies Inc. (” Vocan“), a company operating under one of few Health Canada Controlled Drugs and Substances Dealer’s labs, is pleased to announce that it is in the final stages of completing its provisional patent application for the protection of its proprietary biosynthetic psilocybin production system. Completion of the application is expected in the coming days at which time the provisional application will be made to the United States Patent and Trademark Office.

Over the last four months Vocan has made great strides in further developing its biosynthetic psilocybin production method and has started collecting data to substantiate our drafted provisional patent. As such, we anticipate a forthcoming filing of our provisional patent application.

The process of extracting natural occurring psilocybin from a host plant is inefficient and very expensive, as are synthetic processing techniques. Vocan’s provisional patent application for the biosynthetic processing of psilocybin addresses the many inefficiencies and cost prohibitions of current psilocybin production methods. The established partnership with the University of British Columbia (UBC) and the collaborative approach employed by UBC and Vocan for producing biosynthetic psilocybin will crystallize the possibility of creating a product that is consistent in quality and concentration, and stereochemically comparable to its natural occurring compound. Core One firmly believes that this collaboration will be able to provide the reliability required for empirical, clinical, and medical psychedelic research.

As innovative businesses entering the medical psychedelic market continue to grow and, as more researchers and organizations rush to further develop the therapeutic and medical benefits of psilocybin, the need for a steady and consistent supply chain will also increase. Core One believes that its biosynthetic production of psilocybin holds a wide appeal for developing psychedelics medicines and clinical industries worldwide, and has significant cost reductions and meaningful efficacy enhancements.

“Core One Labs submitting its patent for its revolutionary biosynthetic psilocybin production system is imminent as we are just days away. This could position the Company as the leader in provision of pharmaceutical API grade psilocybin which could ultimately drive value for shareholders and stakeholders alike.  We have assembled a world class team to promote and sell our biosynthesized psilocybin to other major companies that are working on therapeutic psychedelic solutions. With current prices of psilocybin being over $7000 USD per gram, we view this space as being highly profitable,” stated Joel Shacker CEO of the Company.

About Core One Labs Inc.

Core One is a biotechnology research and technology life sciences enterprise focused on bringing psychedelic medicines to market through novel delivery systems and psychedelic assisted psychotherapy. Core One has developed a patent pending thin film oral strip (the “technology”) which dissolves instantly when placed in the mouth and delivers organic molecules in precise quantities to the bloodstream, maintaining excellent bioavailability. The Company intends to further develop and apply the technology to psychedelic compounds, such as psilocybin. Core One also holds an interest in medical clinics which maintain a combined database of over 275,000 patients. Through these clinics, the integration of its intellectual property, R&D related to psychedelic treatments and novel drug therapies, the Company intends to obtain regulatory research approval for the advancement of psychedelic-derived treatments for mental health disorders.

Core One Labs Inc.

Joel ShackerChief Executive Officer

FOR MORE INFORMATION, PLEASE CONTACT: info@core1labs.com 1-866-347-5058

Cautionary Disclaimer Statement:

The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management’s current estimates, beliefs, intentions, and expectations. They are not guarantees of future performance. The Company cautions that all forward-looking statements are inherently uncertain, and that actual performance may be affected by a number of material factors, many of which are beyond the Company’s control. Such factors include, among other things: risks and uncertainties relating to the Company’s limited operating history and the need to comply with strict regulatory regulations. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information.

In addition, psilocybin is currently a Schedule III drug under the Controlled Drugs and Substances Act (Canada) and it is a criminal offence to possess substances under the Controlled Drugs and Substances Act (Canada) without a prescription or authorization. Health Canada has not approved psilocybin as a drug for any indication. Core One does not have any direct or indirect involvement with illegal selling, production, or distribution of psychedelic substances in jurisdictions in which it operates. While Core One believes psychedelic substances can be used to treat certain medical conditions, it does not advocate for the legalization of psychedelics substances for recreational use. Core One does not deal with psychedelic substances, except within laboratory and clinical trial settings conducted within approved regulatory frameworks.

Read more: Core One Labs’ Biosynthesized Psilocybin Provisional Patent Imminent

Incyte (Nasdaq:INCY) today announced that multiple abstracts highlighting updated data for ruxolitinib cream, an investigational topical JAK1/JAK2 inhibitor, in patients with atopic dermatitis (AD) will be presented at the upcoming 2021 Revolutionizing Atopic Dermatitis (RAD) Virtual Conference, held on June 13, 2021.

“Atopic dermatitis, the most common type of eczema, can be difficult to manage and can have a significant impact on patients’ lives,” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation & AutoImmunity, Incyte. “We are pleased to be sharing new data from our Phase 3 TRuE-AD program at the RAD Virtual Conference. These data provide additional insights on the potential role ruxolitinib cream could play as a treatment option for patients living with atopic dermatitis.”

Key abstracts include:

Late-Breaking Oral and Poster Presentation

Long-Term Safety and Disease Control with Ruxolitinib Cream in Atopic Dermatitis: Results from Two Phase 3 Studies

Poster Presentations

Long-Term Safety and Disease Control with Ruxolitinib Cream in Patients with More Severe Atopic Dermatitis: Pooled Results from Two Phase 3 Studies

Long-Term Safety and Disease Control with Ruxolitinib Cream Among Patients with Atopic Dermatitis Based on Previous Medication History: Pooled Results from Two Phase 3 Studies

Predicting Reduction in Lost Productivity and Indirect Costs Among Patients with Atopic Dermatitis Treated with Ruxolitinib Cream

Inadequate Disease Control, Treatment Dissatisfaction, and Quality-of-Life Impairments Among US Patients Receiving Topical Therapy for Atopic Dermatitis

More information regarding the virtual conference is available on the RAD website: https://revolutionizingad.com/. Additionally, meeting abstracts will be published in the British Journal of Dermatology.

About Ruxolitinib Cream

Ruxolitinib cream is a proprietary formulation of Incyte’s selective JAK1/JAK2 inhibitor ruxolitinib that has been designed for topical application. Ruxolitinib cream is currently in Phase 3 development for the treatment of adolescents and adults with atopic dermatitis (TRuE-AD) and vitiligo (TRuE-V). Incyte has worldwide rights for the development and commercialization of ruxolitinib cream.

About Incyte Dermatology

Incyte’s science-first approach and expertise in immunology has formed the foundation of the company. In Dermatology, the Company’s research and development efforts are focused on leveraging our knowledge of the JAK-STAT pathway to identify and develop topical and oral therapies with the potential to modulate immune pathways driving uncontrolled inflammation and help restore normal immune function.

Currently, Incyte is exploring the potential of JAK inhibition for a number of immune-mediated dermatologic conditions with a high unmet medical need, including atopic dermatitis, vitiligo and hidradenitis suppurativa. To learn more, visit the Dermatology section of Incyte.com.

About Incyte

Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte.

Forward-Looking Statements

Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the presentation of data from the Company’s ongoing clinical development program for ruxolitinib cream, its TRuE-AD and TRuE-V programs and its atopic dermatitis, vitiligo and other dermatology programs generally, and whether or when ruxolitinib cream will be approved or commercially available in the U.S. or elsewhere for atopic dermatitis, vitiligo or any other indication, contain predictions, estimates and other forward-looking statements.

These forward-looking statements are based on the Company’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; the effects of the COVID-19 pandemic and measures to address the pandemic on the Company’s clinical trials, supply chain, other third-party providers and development and discovery operations; determinations made by the U.S. FDA and other regulatory authorities outside of the United States; the efficacy or safety of the Company’s products; the acceptance of the Company’s products in the marketplace; market competition; sales, marketing, manufacturing and distribution requirements; and other risks detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission, including its annual report and its quarterly report on Form 10-Q for the quarter ended March 31, 2021. The Company disclaims any intent or obligation to update these forward-looking statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210612005013/en/

Read more: Incyte Announces Updated Data For Ruxolitinib Cream Accepted For Presentation At The 2021 Revolutionizing Atopic Dermatitis (RAD) Virtual Conference

The law firm of Kessler Topaz Meltzer & Check, LLP reminds Romeo Power, Inc. (“Romeo”) (NYSE: RMO; RMO.WT) f/k/a RMG Acquisition Corp. (“RMG”) (NYSE: RMG; RMG.U; RMG.WS) investors that a securities fraud class action lawsuit has been filed on behalf of those who purchased or acquired Romeo securities between October 5, 2020 and March 30, 2021, inclusive (the “Class Period”).

Investor Deadline Reminder: Investors who purchased or acquired Romeo securities during the Class Period may, no later than June 15, 2021, seek to be appointed as a lead plaintiff representative of the class. For additional information or to learn how to participate in this litigation please contact Kessler Topaz Meltzer & Check, LLP: James Maro, Esq. (484) 270-1453 or Adrienne Bell, Esq. (484) 270-1435; toll free at (844) 887-9500; via e-mail at info@ktmc.com; or click https://www.ktmc.com/romeo-powerclass-action-lawsuit?utm_source=PR&utm_medium=Link&utm_campaign=romeo

Romeo is an energy technology company focused on designing and manufacturing lithium-ion battery modules and packs for commercial electric vehicles. RMG, a special purpose acquisition company, or SPAC, was formed for the purpose of entering into a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses in the diversified resources and industrial materials sectors. On October 5, 2020, RMG announced a definitive agreement for a business combination with Romeo. On December 29, 2020, Romeo announced that it completed its business combination with RMG. The business combination was approved by RMG stockholders in a special meeting held on December 28, 2020 and consummated on December 29, 2020.

During the Class Period, the defendants represented that for 2020 Romeo estimated revenue of $11 million, and for 2021 Romeo estimated revenue of $140 million. The defendants further represented that Romeo had the capacity and supply to meet end-user demand for Romeo’s products, that Romeo was not beholden “to any level of the value chain”, that its supply was hedged, and that it did not see any material challenges that would hamper growth.

The truth was revealed on March 30, 2021 when, after the market closed, Romeo issued a press release and filed a report with the U.S. Securities and Exchange Commission on a Form 8-K that disclosed its financial results for the quarter and year ended December 31, 2020, and conducted a conference call with investors and analysts. The defendants shocked investors by disclosing that Romeo’s production had been hampered by a shortage in supply of battery cells and that its estimated 2021 revenue would therefore be reduced by approximately 71-87%. On March 31, 2021, Morgan Stanley issued a research report in which it downgraded Romeo’s target price per share from $12 to $7. Following this news, Romeo shares declined from a closing price on March 30, 2021 of $10.37 per share to close at $8.33 per share, a decline of $2.04 per share, or almost 20%.

The complaint alleges that throughout the Class Period, the defendants concealed that: (1) Romeo had only two battery cell suppliers, not four; (2) the future potential risks that the defendants warned of concerning supply disruption or shortage had already occurred and were already negatively affecting Romeo’s business, operations and prospects; (3) Romeo did not have the battery cell inventory to accommodate end-user demand and ramp up production in 2021; (4) Romeo’s supply constraint was a material hindrance to Romeo’s revenue growth; and (5) Romeo’s supply chain for battery cells was not hedged, but in fact, was totally at risk and beholden to just two battery cell suppliers and the spot market for their 2021 inventory.

Romeo investors may, no later than June 15, 2021 , seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. In order to be appointed as a lead plaintiff, the Court must determine that the class member’s claim is typical of the claims of other class members, and that the class member will adequately represent the class. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.

Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country involving securities fraud, breaches of fiduciary duties and other violations of state and federal law. Kessler Topaz Meltzer & Check, LLP is a driving force behind corporate governance reform, and has recovered billions of dollars on behalf of institutional and individual investors from the United States and around the world. The firm represents investors, consumers and whistleblowers (private citizens who report fraudulent practices against the government and share in the recovery of government dollars). The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP. For more information about Kessler Topaz Meltzer & Check, LLP please visit www.ktmc.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210612005002/en/

Read more: Deadline Alert: Kessler Topaz Meltzer & Check, LLP Alerts Investors Of Lead Plaintiff Deadline In Securities Fraud Class Action Lawsuit Against Romeo Power, Inc.

CHICAGO, June 12, 2021 /PRNewswire/ — As the global nonprofit leader in Alzheimer’s research and science we have extensively reviewed the clinical trial data for Aduhelm ™ (aducanumab). Based on the trial data, the treatment demonstrated an efficacious result which has also been confirmed by leading scientists in the Alzheimer’s and dementia scientific community and the Food and Drug Administration (FDA). Alzheimer’s Association’s research experts and advisors are deeply familiar with the basic and regulatory science that led to the FDA’s decision. They were right to approve this treatment.

Additionally, the FDA appropriately took into account the vast unmet need of the Alzheimer’s community. Aduhelm is certainly not a cure, but at long last it provides many with Alzheimer’s disease and their families an effective treatment. The confirmatory trial should begin promptly.

Our focus has and will continue to be access to this treatment for all likely to benefit. Approval is the fundamental first step to access. The first drug in a category invigorates the field, increases investments in new treatments and encourages greater innovation.

Following approval, the manufacturer, Biogen, announced their intention to price Aduhelm at $56,000 per year. This price is simply unacceptable. For many, this price will pose an insurmountable barrier to access, it complicates and jeopardizes sustainable access to this treatment, and may further deepen issues of health equity. We call on Biogen to change this price.

Next, the path to access turns to the Centers for Medicare & Medicaid Services (CMS). Just as with the FDA, we have the utmost respect for CMS and how they will approach the key decisions ahead. We’re committed to working with them — and with the private payer community — to expedite access for all of those who would likely benefit based on the successful clinical trial. CMS faces difficult policy decisions on how to best accomplish this within the context of the Medicare program, and we stand ready to fully support CMS and private payers in this work for all communities in need.

Alzheimer’s Association

The Alzheimer’s Association leads the way to end Alzheimer’s and all other dementia — by accelerating global research, driving risk reduction and early detection, and maximizing quality care and support. Our vision is a world without Alzheimer’s and all other dementia®. For more information, visit www.alz.org or call the 24/7 Helpline at 800.272.3900.

View original content to download multimedia: http://www.prnewswire.com/news-releases/alzheimers-association-statement-next-steps-for-new-alzheimers-treatment-301311251.html

SOURCE Alzheimer’s Association

Read more: Alzheimer’s Association Statement: Next Steps For New Alzheimer’s Treatment

• SKT will participate in ‘E3 2021’ for the first time as a South Korean telecommunication company and target the global console game market.
• It will present ‘ANVIL,’ ‘Little Witch in the Woods,’ ‘Vapor World,’ and ‘NEOVERSE’ at E3 2021. 
• With the participation of E3, SKT will begin to publish various video games and actively support South Korean game markets.

SEOUL, South Korea, June 12, 2021 /PRNewswire/ — SK Telecom (hereinafter referred to as “SKT”) will participate in the world’s biggest game exhibition, ‘E3 2021’, for the first time as a South Korean telecommunication company to target the global console game market.

However, due to COVID-19, this year’s E3 will be held online through its official web page or mobile application. It is available to sign up as a visitor on the official web page of E3( https://e3expo.com).

SK Telecom (SKM) – Get Report is Korea’s leading ICT company, driving innovations in the areas of mobile communications, media, security, commerce and mobility. Armed with cutting-edge ICT including AI and 5G, the company is ushering in a new level of convergence to deliver unprecedented value to customers. As the global 5G pioneer, SKT is committed to realizing the full potential of 5G through ground-breaking services that can improve people’s lives, transform businesses, and lead to a better society.

SKT boasts unrivaled leadership in the Korean mobile market with over 30 million subscribers, which account for nearly 50 percent of the market. The company now has 49 ICT subsidiaries and annual revenues approaching KRW 18.6 trillion.

For more information, please contact skt_press@sk.com or visit our LinkedIn page www.linkedin.com/company/sk-telecom.

View original content to download multimedia: http://www.prnewswire.com/news-releases/skt-to-participate-in-e3-2021-to-showcase-exciting-korean-games-301310785.html

SOURCE SK Telecom

Read more: SKT To Participate In E3 2021 To Showcase Exciting Korean Games